Ludwig Institute for Cancer Research
The Ludwig Institute for Cancer Research is a global non profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for human benefit.
Program Highlights
Vascular Endothelial Growth Factors
For over seven years, LICR has coordinated and supported a global Program to research angiogenesis and lymphangiogenesis with the aim of developing therapies that could target both processes. The efforts of the Program investigators, drawn from the Melbourne, Stockholm and Uppsala Branches as well as Affiliates in Helsinki and Kuopio (Finland), have identified four of the five known vascular endothelial growth factors (VEGF-B, VEGF-C, VEGF-D and VEGF-E) and two of the four known platelet-derived growth factors (PDGF-C and PDGF-D) as well as a novel receptor, VEGF receptor-3 (VEGFR-3). More »
News
Investigators from the Ludwig Institute for Cancer Research (LICR) Melbourne Center reported today in the journal The Prostate that a potential new reagent could treat prostate tumors with greater specificity and reduced toxicity than many currently used therapies.
November 17, 2008
LICR Research Leads to US Pharmaceutical Licensing Deal
The international Ludwig Institute for Cancer Research (LICR) announced today that one of its spin-off companies, Life Science Pharmaceuticals, has licensed its lead cancer therapy candidate to pharmaceutical company Abbott.